Assessment of Drug Liking In Peri-procedural Clinical Settings

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT07015528
Phase
EARLY_PHASE1
Status
Enrolling By Invitation

Conditions

  • Drug Liking

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Droperidol — DRUG
    Medication administered as a single intravenous dose.
  • Placebo — DRUG
    Matching Placebo given by single intravenous (IV) administration.

Study Details

The purpose of this study is to evaluate whether medications used in peri-procedural clinical settings can modulate drug liking.

Key Dates

Start date
Sep 30, 2025
Status verified
May 2025
Primary completion
Aug 31, 2026
Completion
Aug 31, 2027

Study Design

Enrollment
130 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Droperidol
    Participants receive study drug prior to fentanyl administration before their procedure.
  • Placebo Comparator: Placebo
    Participants receive placebo prior to fentanyl administration before their procedure.

Primary Outcome Measure

Change in Drug Liking Rating [ Time Frame: One minute before and 1, 3, and 5 minutes after fentanyl administration ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford HospitalPalo AltoCalifornia94304-

Find similar trials in Palo Alto, CA

By research site
Stanford Hospital· Palo Alto, CA

Related Studies